In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic therapies, the company's business model, and your plans for scaling the psychedelics therapies.
Shots:
Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients…
